abstract |
The present invention provides a pharmaceutical composition for administration to HCV-infected patients by inhibiting the serine protease activity of hepatitis C virus (HCV) NS3-NS4A protease. A composition containing a compound represented by the following general formula (I) or (II), or a pharmaceutically acceptable salt, ester, or prodrug. [Selection figure] None |